Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder

Far Eastern Memorial Hospital

Status: Unknown

Conditions: Attention Deficit Disorder; Attention Deficit Disorders With Hyperactivity; Hyperkinetic Syndrome

Treatments: Drug: methylphenidate; Behavioral: behavioral modification; Drug: Atomoxetine

Study type: Observational

Funder types: Other

Identifiers

NCT01130467

FEMH-IRB-098034-3

Details and patient eligibility

About

The investigators try to objectively and scientifically explore various brain function impairments in ADHD children by electrophysiologic tests, with and without medication.

Full description

The aims of this study are to explore the various cognitive impairments of ADHD children, to differentiate various subtypes of ADHD children, and to investigate the efficacy of anti-ADHD drugs on various cognitive performance of ADHD children by event-related potentials(ERP).

Children, aged six to 18 years old, are enrolled and assigned to three groups (normal control, pure ADHD, and ADHD with comorbidities). ADHD children fulfill the DSM-IV-TR criteria for the diagnosis of ADHD. ADHD children are evaluated by Chinese version of SNAP-IV Rating Scale for rating ADHD-related symptoms before and after medication. EEG and audiometric testing are required for every participant to exclude dialeptic seizures and hearing impairment respectively.

Methylphenidate (either immediate-release or extended-release formulations) or atomoxetine Hydrochloride is given to ADHD participants.Continuous performance task (CPT) and ERP tasks are applied.

Enrollment: 150 estimated patients

Sex: All

Ages: 6 to 18 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• health children
• or clinical diagnosis of attention-deficit hyperactivity disorder

Exclusion criteria

• hearing impairment
• uncorrectable visual impairment
• epilepsy

Trial design

150 participants in 3 patient groups

Normal control

pure ADHD

Treatment:

Behavioral: behavioral modification

Drug: Atomoxetine

Drug: methylphenidate

ADHD with comorbidity

Treatment:

Behavioral: behavioral modification

Drug: Atomoxetine

Drug: methylphenidate